Agios Pharmaceuticals price target lowered to $52 from $54 at BofA

BofA lowered the firm’s price target on Agios Pharmaceuticals (AGIO) to $52 from $54 and keeps a Buy rating on the shares. While Q1 earnings season will focus on commercial launches for the analyst’s small to mid cap biotech coverage, conversation around pharma tariffs, tax impact, and FDA turnover “should provide an additional overlay to sentiment,” the analyst tells investors in a preview for the group.